Education
About Us
Working with TipRanks
Follow Us
Collplant Holdings (CLGN)
NASDAQ:CLGN
Top Page
Collplant Holdings
(NASDAQ:CLGN)
38Underperform
Positive Factors
Partnerships
CollPlant continues to progress the clinical development of its dermal and soft-tissue filler program in collaboration with AbbVie.
Product Development
Encouraging initial breast implant data shows signs of implant integration and rapid growth of native tissue, supporting potential future commercialization.
Negative Factors
Financial Performance
The company reported total revenues of $0.25M, compared to the consensus estimate of $0.69M.
Collplant Holdings (CLGN) vs. S&P 500 (SPY)
Market Cap
$29.21M
Dividend YieldN/A
Average Volume (3M)9.53K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue Growth-95.30%
EPS Growth-135.89%
CountryUS
Employees57
SectorHealthcare
Sector Strength72
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.45
Shares Outstanding11,454,512
10 Day Avg. Volume21,058
30 Day Avg. Volume9,534
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.24
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$11.00Price Target Upside326.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Collplant Holdings Business Overview & Revenue Model
Company DescriptionCollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
How the Company Makes MoneyCollPlant Holdings generates revenue primarily through the sale and licensing of its proprietary rhCollagen-based products and technologies. The company's key revenue streams include direct product sales, licensing agreements, and collaborations with other biotechnology or pharmaceutical companies. Significant partnerships, such as those with 3D bioprinting firms and aesthetic medicine companies, contribute to its earnings by providing access to broader markets and co-development opportunities. Additionally, CollPlant might receive milestone payments and royalties from partners who utilize its technologies in their own product development.
Collplant Holdings Financial Statement Overview
Summary
Collplant Holdings is facing financial challenges, characterized by significant revenue and cash flow declines, negative profit margins, and shrinking assets and equity. Despite maintaining low debt levels, the company's ability to generate revenue and positive cash flow remains a concern. The biotechnology industry involves substantial R&D investment, which may explain some financial strain, but the current trajectory indicates potential risk without strategic improvements.Income Statement
Collplant Holdings has experienced significant revenue volatility, with a notable revenue decline from $10.96 million in 2023 to $0.515 million in 2024. The company is struggling with negative margins, including a gross profit margin of -215% and a net profit margin of -3226% in 2024. Despite a brief profitable period in 2021, consistent negative EBIT and EBITDA margins indicate ongoing operational challenges.35
Negative
Balance Sheet
The company's debt-to-equity ratio remains low at 0.23 in 2024, reflecting a conservative leverage approach. However, stockholders' equity has decreased significantly, and the equity ratio has dropped from 88% in 2021 to 72% in 2024, indicating weakening financial stability. The company's asset base has also shrunk considerably over the same period.50
Neutral
Cash Flow
Collplant Holdings' free cash flow has deteriorated significantly, with a negative free cash flow of $14.58 million in 2024, compared to $3.72 million in 2023. The operating cash flow to net income ratio and free cash flow to net income ratio are both negative, showing a lack of cash flow generation. Despite previous years of positive cash flow from financing activities, the company's cash reserves are depleting.30
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 515.00K | 10.96M | 299.00K | 15.64M | 6.14M | Gross Profit |
| -1.11M | 8.97M | -101.00K | 13.64M | 3.13M | EBIT |
| -17.25M | -7.51M | -17.10M | 65.00K | -5.60M | EBITDA |
| -16.21M | -6.41M | -16.02M | 838.00K | -4.94M | Net Income Common Stockholders |
| -16.61M | -7.02M | -16.75M | 409.00K | -5.81M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 11.91M | 26.67M | 29.65M | 43.30M | 3.33M | Total Assets |
| 18.71M | 34.13M | 37.77M | 51.22M | 10.84M | Total Debt |
| 3.08M | 3.16M | 2.91M | 3.61M | 3.39M | Net Debt |
| -8.83M | -23.52M | -26.74M | -9.54M | 55.00K | Total Liabilities |
| 5.25M | 5.79M | 5.49M | 6.10M | 6.36M | Stockholders Equity |
| 13.46M | 28.34M | 32.28M | 45.12M | 4.48M |
| Cash Flow | Free Cash Flow | |||
| -14.58M | -3.72M | -15.01M | 912.00K | -4.97M | Operating Cash Flow |
| -14.09M | -2.76M | -13.70M | 2.50M | -4.45M | Investing Cash Flow |
| -539.00K | -1.16M | 28.92M | -31.56M | -519.00K | Financing Cash Flow |
| 9.00K | 1.11M | 1.87M | 38.76M | 4.46M |
Collplant Holdings Technical Analysis
Negative
2.58
Price Trends
3.41
Negative
3.69
Negative
4.23
Negative
Market Momentum
-0.22
Positive
27.50
Positive
4.18
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLGN, the sentiment is Negative. The current price of 2.58 is below the 20-day moving average (MA) of 3.02, below the 50-day MA of 3.41, and below the 200-day MA of 4.23, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 27.50 is Positive, neither overbought nor oversold. The STOCH value of 4.18 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLGN.
Collplant Holdings Risk Analysis
Collplant Holdings disclosed 81 risk factors in its most recent earnings report. Collplant Holdings reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Collplant Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $570.73M | 771.43 | 0.26% | ― | 11.29% | -79.52% | |
67 Neutral | $1.11B | 26.50 | 25.01% | ― | 8.52% | -32.91% | |
55 Neutral | $230.10M | ― | -230.96% | ― | 32.24% | -66.93% | |
48 Neutral | $6.84B | 1.02 | -53.11% | 2.50% | 16.84% | 0.92% | |
46 Neutral | $74.38M | ― | -80.11% | ― | -7.43% | 69.03% | |
42 Neutral | $13.98M | ― | -61.87% | ― | ― | 11.66% | |
38 Underperform | $29.21M | ― | -79.46% | ― | -95.30% | -135.89% |
* Healthcare Sector Average
Performance Comparison
CLGN
Collplant Holdings
2.58
-2.68
-50.95%
VERU
Veru
0.49
-0.27
-35.53%
RCEL
Avita Medical
8.14
-7.41
-47.65%
MDXG
MiMedx Group
7.60
0.15
2.01%
ORGO
Organogenesis Holdings
4.32
1.52
54.29%
NXTC
NextCure
0.48
-1.83
-79.22%
Collplant Holdings Earnings Call Summary
Earnings Call Date: Mar 26, 2025 | % Change Since: -7.86% | Next Earnings Date: May 22, 2025
Earnings Call Sentiment Neutral
Despite significant advancements in preclinical programs and continued collaboration with AbbVie, the company experienced a sharp decline in annual revenue and increased net losses, presenting a mixed financial outlook.Highlights
Photocurable Dermal Filler Preclinical Success
The photocurable dermal filler candidate is in the preclinical phase, targeting a market valued at approximately $6.3 billion with a compound annual growth rate of 10%. Positive feedback from leaders in aesthetic medicine suggests it could be a game-changer for facial plastic surgery.
Regenerative Breast Implant Program Progress
Preclinical testing of commercial-sized breast implants (250cc) shows promising outcomes with depolarization and rapid tissue ingrowth, no complications, and maintained volume retention. This product could revolutionize breast reconstruction and aesthetic enhancements.
AbbVie Collaboration and Financial Milestone
CollPlant received a $2 million payment from AbbVie following development achievements in their dermal filler clinical trials, indicative of continued collaboration and potential future milestones.
Cash Runway Stability
Cash and cash equivalents as of December 31, 2024, were $11.9 million, with an expected operational runway through the second quarter of 2026.
Lowlights
Significant Revenue Decline
Revenue for the year ended December 31, 2024, was $515,000, a sharp decrease from $11 million in 2023, mainly due to a $10 million milestone payment in 2023 not repeated in 2024.
Increased Net Loss
GAAP net loss for the year ended December 31, 2024, was $16.6 million compared to a net loss of $7 million for the year 2023, highlighting increased financial strain.
Company Guidance
During the CollPlant Biotechnologies Ltd. investor call, CEO Yehiel Tal and Deputy CEO Eran Rotem provided guidance centered on their regenerative medicine advancements, notably highlighting their proprietary photocurable dermal filler and regenerative breast implant programs. The dermal filler, aimed at a market valued at approximately $6.3 billion with a 10% CAGR, is currently in the preclinical phase, with plans to launch a clinical trial within two years. The regenerative breast implant program is progressing with preclinical testing of 250cc commercial-sized prototypes, showing promising results in tissue integration without complications. Financially, CollPlant reported a decrease in revenue from $11 million in 2023 to $515,000 in 2024, primarily due to a $10 million milestone payment from AbbVie in 2023. Despite a GAAP net loss of $16.6 million in 2024 compared to $7 million in 2023, the company maintains a stable cash position of $11.9 million as of December 31, 2024, not accounting for an additional $2 million payment from AbbVie, ensuring operational capability into the second quarter of 2026.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.